MedPath

Clinical Trials for the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer

Phase 3
Completed
Conditions
Gastric Cancer
Interventions
Drug: Placebo
Registration Number
NCT02490111
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Brief Summary

This study evaluates the efficacy and safety of DWJ1319 in the prevention of gallstone formation after gastrectomy in patient with gastric cancer. Two-thirds of the participants will receive DWJ1319, while the other will receive a placebo.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
521
Inclusion Criteria
  • Male or female at least 19 years of age
  • Patient who undergoes gastrectomy (total, distal or proximal gastrectomy)
  • D1+ or D2 lymph node dissection
  • Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale
  • Written informed consent
Exclusion Criteria
  • Patients with cholangitis, cholecystitis, non-functional gall bladder, or biliary obstruction
  • Presence of gallstones on ultrasonography and/or CT
  • History of previous cholecystectomy
  • Patients undergoing pylorus-preserving gastrectomy
  • Pregnant or lactating women and fertile women who is not using proper contraceptive method
  • Patients with history of drug or alcohol abuse within 5 years ago

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
DWJ1319 300 mg BIDDWJ1319DWJ1319 300 mg, orally, twice daily (BID) for up to 12 months
DWJ1319 300 mg QDDWJ1319DWJ1319 300 mg, orally, once daily (QD), and DWJ1319 placebo-matching capsules, orally, once daily for up to 12 months
DWJ1319 300 mg QDPlaceboDWJ1319 300 mg, orally, once daily (QD), and DWJ1319 placebo-matching capsules, orally, once daily for up to 12 months
PlaceboPlaceboPlacebo, orally, twice daily (BID) for up to 12 months
Primary Outcome Measures
NameTimeMethod
Proportion of patient developing gallstone at 12 month after gastrectomy12 months
Secondary Outcome Measures
NameTimeMethod
Proportion of patient developing gallstone at 3, 6 and 9 month after gastrectomy3, 6 and 9 months
Time to gallstone formation12 months

Trial Locations

Locations (12)

Yonsei University Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

National Cancer Center

🇰🇷

Goyang-si, Gyeonggi-do, Korea, Republic of

Chonnam National University Hwasun Hospital

🇰🇷

Hwasun, Jeollanam-do, Korea, Republic of

Kyungpook National university Chilgok Hospital

🇰🇷

Daegu, Korea, Republic of

Chungnam National university hospital

🇰🇷

Daejeon, Korea, Republic of

Ajou University Hospital

🇰🇷

Suwon, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

The Catholic University of Korea, Seoul St. Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul Natioanl University Bundang Hospital

🇰🇷

Seongnam-si, Gyeonggi-do, Korea, Republic of

Seoul Metropolitan Government Seoul National University Boramae Medical Center

🇰🇷

Seoul, Korea, Republic of

Pusan National University Yangsan Hospital

🇰🇷

Yangsan, Kyeongsangnamdo, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath